On March 16th, 2020, Austria went into the first lockdown. Only a few days later we decided to get involved and use our knowledge about PCR and diagnostics to combat the COVID-19 pandemic. Below you can find out about what has happened since then in the last 365 days at TAmiRNA.
TAmiRNA SARS-CoV-2 Virus PCR Test Service
Based on a great team effort, we successfully established our diagnostic SARS-CoV-2 PCR service, and ran the first patient samples on April 16th, exactly one month after the pandemic had hit Austria. Since then, no day has passed without patient samples passing through our lab. We have tested more than 30,000 samples from our customers, families, and friends and have continued to expand our services from SARS-CoV-2 N-gene screening assays to 25-plex respiratory virus panels and SARS-CoV-2 N501Y/E484K genotyping assays.
SARS CoV-2 Antigen Tests
In August 2020 rapid antigen testing emerged in Europe to complement laboratory-based PCR testing. We established mobile testing teams that move on-site to our partners and we collaborate with Austrian start-up easytest service GmbH to provide test services to the tourism and catering industry within a project called "Sichere Gastfreundschaft". Furthermore, we distribute selected minimal-invasive SARS-CoV-2 antigen tests, which have been cleared for self-application in Austria.
NEW: TAmiRNA SARS CoV-2 Antibody Test
With the approval of Pfizer/BioNTechs BNT162 vaccine in Europe at the end of 2020, we start to see light at the end of the tunnel. In order to monitor proper immune responses following vaccination, our team set out to develop and manufacture our own antibody test that can detect neutralizing IgM and IgG antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This lateral flow assay was just launched in March 2021 as a CE-IVD test and data support the test's ability to detect immune responses in BNT162 vaccinated persons within 14 days after the first injection.
But of course, we have remained dedicated to the world of microRNAs and small RNAs during all that time. We have expanded our small RNAseq and RNAseq services to extracellular vesicles and microdissected tissues to enable space-resolved transcriptome analyses. Together with our partners we have published > 15 peer-reviewed articles and progressed our biomarker pipeline within IMI2, Eurostars, and national (FFG) projects. Click below to browse through our website to find out more about our recent activities.
Additional information is available at https://www.tamirna.com/